Next Article in Journal / Special Issue
Association of OCT-Derived Drusen Measurements with AMD-Associated Genotypic SNPs in the Amish Population
Previous Article in Journal
HPV Carcinomas in Immunocompromised Patients
Previous Article in Special Issue
NLRP3 Inflammasome and Pathobiology in AMD
Article Menu

Export Article

Open AccessReview
J. Clin. Med. 2015, 4(2), 282-303; doi:10.3390/jcm4020282

Tapping Stem Cells to Target AMD: Challenges and Prospects

1
Institute of Human Genetics, University of Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany
2
Department of Ophthalmology, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, 93042 Regensburg, Germany
*
Author to whom correspondence should be addressed.
Academic Editors: Margaret DeAngelis and Lindsay Farrer
Received: 1 September 2014 / Accepted: 13 January 2015 / Published: 29 January 2015
(This article belongs to the Special Issue Age-Related Macular Disease)
View Full-Text   |   Download PDF [437 KB, uploaded 29 January 2015]   |  

Abstract

Human pluripotent stem cells (hPSCs) are increasingly gaining attention in biomedicine as valuable resources to establish patient-derived cell culture models of the cell type known to express the primary pathology. The idea of “a patient in a dish” aims at basic, but also clinical, applications with the promise to mimic individual genetic and metabolic complexities barely reflected in current invertebrate or vertebrate animal model systems. This may particularly be true for the inherited and complex diseases of the retina, as this tissue has anatomical and physiological aspects unique to the human eye. For example, the complex age-related macular degeneration (AMD), the leading cause of blindness in Western societies, can be attributed to a large number of genetic and individual factors with so far unclear modes of mutual interaction. Here, we review the current status and future prospects of utilizing hPSCs, specifically induced pluripotent stem cells (iPSCs), in basic and clinical AMD research, but also in assessing potential treatment options. We provide an outline of concepts for disease modelling and summarize ongoing and projected clinical trials for stem cell-based therapy in late-stage AMD. View Full-Text
Keywords: stem cells; induced pluripotent stem cells (iPSCs); retinal pigment epithelium (RPE); age-related macular degeneration (AMD); disease modelling; drug screening; cell-based transplantation therapy; RNA-sequencing stem cells; induced pluripotent stem cells (iPSCs); retinal pigment epithelium (RPE); age-related macular degeneration (AMD); disease modelling; drug screening; cell-based transplantation therapy; RNA-sequencing
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Brandl, C.; Grassmann, F.; Riolfi, J.; Weber, B.H.F. Tapping Stem Cells to Target AMD: Challenges and Prospects. J. Clin. Med. 2015, 4, 282-303.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top